View Post

Phase I clinical trial of PAC-1 in patients with end-stage cancers shows promising results

In In The News by Barbara Jacoby

Source: University of Illinois at Urbana-Champaign From: A phase I clinical trial of PAC-1, a drug that spurs programmed cell death in cancer cells, found only minor side effects in patients with end-stage cancers. The drug stalled the growth of tumors in the five people in the trial with neuroendocrine cancers and reduced tumor size in two of those …